-
The most common cancers for men and women in 2024
Of all cancer cases in men in 2024, 48% are predicted to be prostate, lung and colon and rectum and 51% of all new cases in women are expected to be from breast, lung and colon and rectum cancers, researchers from the American Cancer Society found. -
Houston oncologist develops treatment that touts 50% complete remission
A "legendary" Houston oncologist has developed a novel cancer treatment that boasts a complete remission rate among patients of 50%, ABC7 reported Feb. 3. -
6 cancer vaccines showing promise
Here are six cancer vaccines showing promise or in development since May 2023: -
2 types of cancer that may soon have a vaccine
Early trials of a vaccine that targets a specific gene found in tumors, known as KRAS, has proven to be effective in 84% of patients who had pancreatic or colorectal cancers recur after their initial treatment, according to researchers at Memorial Sloan Kettering Cancer Center in New York City who co-led the study. -
UAMS steps closer to NCI designation
Little Rock-based University of Arkansas for Medical Sciences reached its $30 million fundraising goal and is closer to becoming a national cancer institute. -
Global cancer rates to spike 77% by 2050
New estimates suggest that global cancer cases will spike around 77% by 2050, according to a Feb. 1 United Nations report. -
Rutgers cancer center promotes 2 leaders
The Rutgers Cancer Institute of New Jersey has promoted two leadership positions to better situate it for support of the new Jack and Sheryl Morris Cancer Center in New Brunswick, N.J., set to open in early 2025. -
MD Anderson 1st in US to partner with international nuclear agency
Houston-based University of Texas MD Anderson Cancer Center is the first International Atomic Energy Agency Collaborating Centre in the United States focused on healthcare. -
NYU Langone names neuro-oncology chief
Alexandra Miller, MD, PhD, a neurologist and neuro-oncologist who specializes in brain tumors, was named chief of the neuro-oncology program and co-director of the Brain and Spine Tumor Center at New York City-based NYU Langone's Perlmutter Cancer Center. -
Not all cancer should be called cancer, some physicians say
Calling the lowest-risk prostate cancers something else may encourage some patients to follow physicians' treatment recommendations of active surveillance and avoid pursuing more aggressive options, according to a growing number of physicians advocating for a change in nomenclature, The Wall Street Journal reported Jan. 24. -
900+ chemicals in consumer products tied to breast cancer risk, study says
Researchers have identified 921 chemicals thought to increase the risk of breast cancer and say none should be considered "low hazard" until further investigation is done. -
Cedars-Sinai AI tool accurately detects pancreatic cancer
Los Angeles-based Cedars-Sinai is using artificial intelligence to improve prediction of and treatment for pancreatic cancer, according to a Jan. 22 news release. -
How innovative testing is helping Mercy screen for cancer early — 3 key takeaways
In an interactive session hosted by GRAIL at Becker's 11th Annual CEO + CFO Roundtable, Roni Christopher, DHSc, senior director of care delivery at GRAIL, and Adam Whitten, vice president of operations at Mercy (St. Louis), discussed how multi-cancer early detection testing can support health systems and patient outcomes. -
Melanoma vaccine shows promise; approved for phase 3 trial
Biotech company Orbis Health Solutions was approved to begin a phase 3 clinical trial of its melanoma vaccine, ABC News reported Jan. 20. -
Cancer centers' masking approaches vary in wake of viruses' resurgence
This is the first year since the COVID-19 pandemic began that hospitals must independently decide if and how to implement masking, and cancer centers across the country are taking different approaches. -
UCLA Health names chief of breast surgery
Los Angeles-based UCLA Health appointed Mediget Teshome, MD, chief of breast surgery and director of breast health. -
FDA approves 1st AI-powered device for skin cancer detection
The FDA recently approved the nation's first artificial intelligence-powered medical device that detects skin cancer. -
Drugmakers turn to class of cancer drugs to fuel growth in 2024
Drugmakers have their sights set on a class of cancer drugs known as antibody drug conjugates, or ADCs, to drive growth, CNBC reported Jan. 14. -
New cancer diagnoses set to hit a new high in 2024: American Cancer Society
The expected increase in new cancer diagnoses this year is record-setting, even as overall cancer mortality is expected to continue its decline, the American Cancer Society said in its latest report. -
5 cancer types with highest risk of a substance use disorder: Study
Substance use disorders are highly variable among cancer patient populations, and new research points to five cancers with the highest prevalence of SUDs, according to a study published Jan. 11 in JAMA.
Page 11 of 50